Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7573297 | 0.86 | SIGMAR1 (0.56) | LMNAMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL15341688 | 0.86 | TSHR (0.44) | SIGMAR1 | |
| SCHEMBL4844085 | 0.85 | SIGMAR1 (0.62) | LMNAMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL4844073 | 0.85 | SIGMAR1 (0.62) | LMNAMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL27929970 | 0.82 | LMNA (0.53) | LMNAMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL5557549 | 0.81 | SIGMAR1 (0.68) | LMNAMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL5557553 | 0.81 | SIGMAR1 (0.68) | LMNAMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL3494735 | 0.80 | SIGMAR1 (0.80) | LMNAMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL4836976 | 0.80 | SIGMAR1 (0.80) | LMNAMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL31421250 | 0.80 | LMNA (0.60) | LMNAMEN1KMT2ASIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | LMNA 201/4885MEN1 750/4885KMT2A 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.